科研动态PubMed 摘要

基于PARP抑制剂联合方案一线治疗转移性去势抵抗性前列腺癌:一项荟萃分析。

PubMed 白名单日捞 · 2026-11-10

完整摘要 · 中文译文

聚(ADP-核糖)聚合酶(PARP)抑制剂联合雄激素受体通路抑制剂(ARPI)已成为转移性去势抵抗性前列腺癌(mCRPC)一种有前景的治疗策略。我们对评估PARP抑制剂-ARPI联合方案用于一线mCRPC治疗的III期研究进行了系统评价和荟萃分析。系统检索了PubMed/MEDLINE、Embase、Web of Science、Cochrane对照试验中心注册库和ClinicalTrials.gov。符合条件的研究为随机III期试验,比较PARP抑制剂联合ARPI与相应以ARPI为基础的对照方案用于一线mCRPC。主要终点为无进展生存期(PFS),总生存期(OS)为关键次要终点。共纳入三项III期试验(PROpel、MAGNITUDE和TALAPRO-2),包含2,024例患者。与单纯以ARPI为基础的治疗相比,PARP抑制剂-ARPI联合方案显著改善PFS(HR 0.66,95%置信区间[CI] 0.58-0.76;P < 0.001),相当于疾病进展或死亡风险降低34%。同时观察到显著的OS获益(HR 0.79,95% CI 0.70-0.89;P < 0.001),相当于死亡风险降低21%。两个终点均未观察到异质性(I² = 0%)。在BRCA1/2改变的患者中,治疗效果更为明显,PFS的合并HR为0.40(95% CI 0.31-0.53),OS的合并HR为0.55(95% CI 0.42-0.71)。联合治疗与血液学毒性增加相关,尤其是贫血,但不良事件总体可控。 . PARP抑制剂联合ARPI显著改善一线mCRPC的无进展生存期和总生存期(OS),在BRCA1/2突变的肿瘤中观察到最大获益。

完整摘要 · 英文原文

Poly(ADP-ribose) polymerase (PARP) inhibitors combined with androgen receptor pathway inhibitors (ARPIs) have emerged as a promising therapeutic strategy for metastatic castration-resistant prostate cancer (mCRPC). We performed a systematic review and meta-analysis of phase III studies evaluating PARP inhibitor-ARPI combinations in the first-line mCRPC setting. PubMed/MEDLINE, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were systematically searched. Eligible studies were randomized phase III trials comparing a PARP inhibitor plus an ARPI with the corresponding ARPI-based control regimen in first-line mCRPC. The primary endpoint was progression-free survival (PFS), while overall survival (OS) was a key secondary endpoint. Three phase III trials (PROpel, MAGNITUDE, and TALAPRO-2) comprising 2,024 patients were included. PARP inhibitor-ARPI combinations significantly improved PFS compared with ARPI-based therapy alone (HR 0.66, 95% confidence interval [CI] 0.58-0.76; P < 0.001), corresponding to a 34% reduction in the risk of progression or death. A significant OS benefit was also observed (HR 0.79, 95% CI 0.70-0.89; P < 0.001), representing a 21% reduction in mortality risk. Heterogeneity was absent for both endpoints (I² = 0%). In patients with BRCA1/2 alterations, treatment effects were more pronounced, with pooled HRs of 0.40 (95% CI 0.31-0.53) for PFS and 0.55 (95% CI 0.42-0.71) for OS. Combination therapy was associated with increased hematologic toxicity, particularly anemia, but adverse events were generally manageable. PARP inhibitor-ARPI combinations significantly improve progression-free and OS in first-line mCRPC, with the greatest benefit observed in BRCA1/2-altered tumors.

English
PARP inhibitor-based combinations in first-line metastatic castration-resistant prostate cancer: A meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界